Iovance Biotherapeutics (IOVA) AI Stock Analysis

• Market Cap: $913.03M
• Dividend Yield: N/A
• Average Volume (3M): 16.49M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.98
• Revenue Growth: 175.62%
• EPS Growth: 19.63%
• Country: US
• Employees: 838
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.25
• Shares Outstanding: 396,967,960
• 10 Day Avg. Volume: 26,544,982
• 30 Day Avg. Volume: 16,486,462
• PEG Ratio: 0.18
• Price to Book (P/B): 3.02
• Price to Sales (P/S): 13.07
• P/FCF Ratio: -5.89
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: 2.16
• Enterprise Value/Gross Profit: 5.58
• Enterprise Value/Ebitda: -1.47
• 1Y Price Target: $6.50
• Price Target Upside: 182.61% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $2.50 ▲(8.70% Upside)

Iovance Biotherapeutics' overall stock score reflects significant financial challenges, with persistent losses and negative cash flows. However, the earnings call provided a positive outlook with revenue growth and strategic restructuring efforts. Technical analysis shows moderate bullish momentum, but valuation remains a concern due to negative earnings. The company's focus on expanding its treatment centers and promising clinical data are positive indicators for future growth.

Positive Factors

Revenue Growth

The consistent revenue growth indicates strong demand for Iovance's products, suggesting successful market penetration and potential for future expansion.

Manufacturing Transition

Centralizing manufacturing is expected to reduce costs and improve margins, enhancing long-term profitability and operational efficiency.

Strong Cash Position

A strong cash position provides financial flexibility to invest in R&D and expansion, supporting long-term strategic initiatives and stability.

Negative Factors

Profitability Challenges

Persistent profitability challenges highlight the need for strategic improvements to achieve financial stability and long-term viability.

Expense Management

Effective expense management is critical to improving margins and achieving sustainable profitability, impacting long-term financial health.

Global Market Expansion Challenges

Delays in global market expansion could limit revenue growth opportunities, impacting the company's ability to scale and diversify income streams.

Iovance Biotherapeutics Business Overview & Revenue Model

Company Description

Iovance Biotherapeutics, Inc. is a biotechnology company focused on developing and commercializing cell therapy products for cancer treatment. The company's core technology centers on tumor-infiltrating lymphocyte (TIL) therapy, which harnesses the patient's own immune cells to target and destroy cancer cells. Iovance is primarily engaged in the research and development of innovative therapies for solid tumors, with its lead product candidate, lifileucel, aimed at treating metastatic melanoma and other cancers.

How the Company Makes Money

Iovance Biotherapeutics generates revenue primarily through the commercialization of its cell therapy products, including lifileucel, once approved by regulatory authorities. The company also engages in partnerships and collaborations with larger pharmaceutical companies for research and development support, which can include upfront payments, milestone payments, and royalties on future sales. Additionally, Iovance may receive funding through grants or other financial support aimed at advancing its clinical programs. The successful transition of its products from clinical trials to market approval is crucial for its revenue generation.

Iovance Biotherapeutics Financial Statement Overview

Summary

Iovance Biotherapeutics faces significant financial challenges, with persistent losses and negative cash flows. Despite modest revenue growth and a strong equity position, the company struggles with profitability and cash flow generation. The low leverage is a positive aspect, but the negative return on equity and margins highlight the need for strategic improvements.

Income Statement

Iovance Biotherapeutics shows a modest revenue growth rate of 3.69% in the TTM, but the company is struggling with profitability. The net profit margin is significantly negative at -161.44%, indicating substantial losses relative to revenue. The EBIT and EBITDA margins are also deeply negative, reflecting high operational costs and challenges in achieving profitability.

Balance Sheet

The company's debt-to-equity ratio is relatively low at 0.08, suggesting conservative leverage. However, the return on equity is negative at -52.87%, indicating that the company is not generating profits from its equity base. The equity ratio stands at 77.57%, showing a strong equity position relative to total assets, which is a positive aspect.

Cash Flow

Iovance Biotherapeutics has a negative operating cash flow and free cash flow, although there is a slight improvement in free cash flow growth at 8.74% in the TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is slightly better than net income, but still negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	250.43M	164.07M	1.19M	0.00	0.00	0.00
Gross Profit	97.07M	40.08M	-9.57M	0.00	0.00	0.00
EBITDA	-368.31M	-351.67M	-427.43M	-377.74M	-328.72M	-260.80M
Net Income	-397.63M	-372.18M	-444.04M	-395.89M	-342.25M	-259.58M
Balance Sheet
Total Assets	904.95M	910.43M	780.35M	663.98M	777.33M	768.46M
Cash, Cash Equivalents and Short-Term Investments	300.80M	323.78M	279.87M	471.85M	504.41M	629.44M
Total Debt	52.49M	58.26M	75.86M	85.45M	71.53M	51.66M
Total Liabilities	202.66M	200.02M	195.74M	164.34M	155.67M	111.96M
Stockholders Equity	702.29M	710.40M	584.61M	499.64M	621.66M	656.50M
Cash Flow
Free Cash Flow	-351.82M	-364.05M	-384.11M	-313.18M	-265.51M	-251.93M
Operating Cash Flow	-323.14M	-352.98M	-361.82M	-292.76M	-227.94M	-205.13M
Investing Cash Flow	70.40M	-96.41M	-155.24M	256.45M	132.00K	-317.85M
Financing Cash Flow	246.91M	390.66M	462.96M	190.15M	239.27M	576.42M

Iovance Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IOVA, the sentiment is Positive. The current price of 2.3 is above the 20-day moving average (MA) of 2.28, above the 50-day MA of 2.22, and below the 200-day MA of 2.69, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 55.30 is Neutral, neither overbought nor oversold. The STOCH value of 68.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IOVA.

Iovance Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMTX	56 Neutral	$1.29B	―	-29.01%	―	-27.61%	-69.49%
IOVA	53 Neutral	$913.03M	―	-53.89%	―	175.62%	19.63%
AMLX	52 Neutral	$1.65B	―	-56.52%	―	-100.34%	52.85%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VIR	51 Neutral	$889.01M	―	-49.06%	―	-78.55%	7.74%
KALV	45 Neutral	$712.70M	―	―	―	―	-13.14%
NUVB	45 Neutral	$2.75B	―	-52.49%	―	1137.19%	70.51%

Iovance Biotherapeutics Corporate Events

Iovance Biotherapeutics Reports Strong Q3 2025 Growth

Iovance Biotherapeutics, Inc. is a biotechnology company specializing in the development of tumor infiltrating lymphocyte (TIL) therapies aimed at treating cancer by leveraging the immune system’s natural ability to target and destroy cancer cells. The company is recognized for its innovative approach in cell therapy, particularly in solid tumors.

Iovance Biotherapeutics Reports Positive Earnings Amid Growth

The recent earnings call of Iovance Biotherapeutics exuded a largely positive sentiment, underscored by substantial revenue growth, strategic restructuring success, and encouraging clinical data in lung cancer. Despite these achievements, the company acknowledged ongoing challenges in managing expenses, expanding globally, and increasing the adoption of community ATCs.

Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study

Study Overview: Iovance Biotherapeutics is conducting a Phase 2 study titled ‘A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Endometrial Cancer.’ The study aims to assess the efficacy and safety of the lifileucel regimen in patients with advanced endometrial cancer who have undergone prior treatments. This research is significant as it explores a potential new treatment avenue for a challenging cancer type.

Iovance Biotherapeutics’ Phase 3 Study: A Potential Game-Changer in Melanoma Treatment

Study Overview: Iovance Biotherapeutics is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma. The study aims to evaluate the effectiveness and safety of combining lifileucel with pembrolizumab versus using pembrolizumab alone in treating advanced melanoma, a significant concern due to its aggressive nature and limited treatment options.

Iovance Biotherapeutics Advances TIL Therapy in Pediatric Cancer Study

Iovance Biotherapeutics is conducting a Phase 1 clinical study titled A Phase 1, Multicenter, Open-label, 2-stage, Single-arm Study to Evaluate the Safety and Tolerability of an Autologous Tumor-infiltrating Lymphocytes (TIL) Regimen and Preliminary Antitumor Activity of TIL in Pediatric, Adolescent, and Young Adult Participants With Relapsed or Refractory Solid Tumors. The study aims to assess the safety and effectiveness of TIL therapy in young patients with solid tumors that have relapsed or are unresponsive to standard treatments.

Iovance Biotherapeutics’ Promising Phase 2 Study on LN-145 for Lung Cancer

Study Overview: Iovance Biotherapeutics is conducting a Phase 2 multicenter study titled ‘A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer.’ The study aims to evaluate the efficacy of LN-145, a treatment for patients with metastatic non-small-cell lung cancer, highlighting its potential significance in advancing cancer therapy.

Iovance Biotherapeutics’ Innovative Cancer Study: A Potential Game-Changer?

Study Overview: Iovance Biotherapeutics is conducting a Phase 2 study titled A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors. The study aims to evaluate the effectiveness of adoptive cell therapy using tumor infiltrating lymphocytes (TIL) in combination with immune checkpoint inhibitors or as a standalone treatment for various solid tumors, including metastatic melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer. This study is significant as it explores innovative cancer treatments that could potentially improve patient outcomes.

Iovance Biotherapeutics Advances Melanoma Treatment with New Study

Study Overview: Iovance Biotherapeutics is conducting a Phase 1/2 study titled ‘A Phase 1/2, Open-label Study of a Modified Interleukin-2 Fusion Protein (IOV-3001) in Participants With Previously Treated, Unresectable or Metastatic Melanoma Who Will Receive Lifileucel.’ The study aims to evaluate the safety and efficacy of IOV-3001 in adults with advanced melanoma, focusing on those who have previously undergone treatment. This research is significant as it explores new therapeutic options for melanoma patients with limited treatment alternatives.

Iovance Biotherapeutics Advances Cancer Treatment with IOV-4001 Study Update

Study Overview: Iovance Biotherapeutics is conducting a Phase 1/2 study titled ‘A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer.’ The study aims to evaluate the efficacy and safety of IOV-4001, a novel treatment for advanced melanoma and non-small-cell lung cancer, highlighting its potential significance in improving patient outcomes in these challenging conditions.

Iovance Biotherapeutics Updates Corporate Presentation

On August 29, 2025, Iovance Biotherapeutics updated its corporate presentation for use at healthcare conferences and with analysts and stockholders. The presentation highlights the company’s progress in TIL therapy, including the commercial launch of products like Amtagvi and Proleukin, and outlines ongoing clinical trials and regulatory submissions, which could impact its market positioning and stakeholder interests.

The most recent analyst rating on (IOVA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics Amends Sale Agreement with Jefferies

On August 22, 2025, Iovance Biotherapeutics entered into an Amended and Restated Open Market Sale Agreement with Jefferies LLC for an at-the-market offering program. This agreement allows the company to issue and sell up to $350 million of its common stock, with Jefferies acting as the sales agent. The sale of shares will be conducted under a prospectus supplement to the company’s registration statement, and Jefferies will receive a commission of up to 3% on the gross sales proceeds. This strategic move could enhance Iovance’s financial flexibility and strengthen its market position.

The most recent analyst rating on (IOVA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics Gains Health Canada Approval

On August 18, 2025, Iovance Biotherapeutics announced that its product Amtagvi® (lifileucel) received approval from Health Canada for use in advanced melanoma patients who have progressed after anti-PD-1 and targeted therapies. This approval marks Iovance’s first marketing authorization outside the U.S., based on the C-144-01 trial results, and signifies a strategic step in addressing unmet needs in solid tumor cancers, with plans to authorize a Canadian treatment center soon.

The most recent analyst rating on (IOVA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics’ Earnings Call Highlights Growth

Iovance Biotherapeutics’ recent earnings call was marked by a generally positive sentiment, driven by strong revenue growth, promising clinical data, and strategic restructuring aimed at cost savings. However, the company also faces challenges, such as increased expenses and the withdrawal of an EMA submission.